Esomeprazole

Generic Name
Esomeprazole
Brand Names
Nexium, Vimovo, Nexium Control
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
119141-88-7
Unique Ingredient Identifier
N3PA6559FT
Background

Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...

Indication

Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
Associated Therapies
-
Clinical Trials
Related News

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Phase 4
Completed
Conditions
GERD
First Posted Date
2005-10-21
Last Posted Date
2009-03-06
Lead Sponsor
AstraZeneca
Target Recruit Count
350
Registration Number
NCT00242736
Locations
🇺🇸

Research Site, Norfolk, Virginia, United States

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Phase 3
Completed
Conditions
NSAIDs
Upper GI Symptoms
First Posted Date
2005-10-19
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
556
Registration Number
NCT00241527
Locations
🇬🇧

Research Site, Yoxall, United Kingdom

🇸🇪

Sweden, Gävle, Sweden

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Phase 3
Completed
Conditions
GERD
First Posted Date
2005-10-19
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
808
Registration Number
NCT00241540
Locations
🇪🇸

Research Site, Zaragoza, Spain

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Phase 3
Completed
Conditions
NSAIDs
Upper GI Symptoms
First Posted Date
2005-10-19
Last Posted Date
2011-01-24
Lead Sponsor
AstraZeneca
Target Recruit Count
276
Registration Number
NCT00241553
Locations
🇬🇧

Research Site, Yoxall, United Kingdom

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Phase 3
Completed
Conditions
GERD
First Posted Date
2005-10-19
Last Posted Date
2011-01-21
Lead Sponsor
AstraZeneca
Target Recruit Count
334
Registration Number
NCT00241514
Locations
🇪🇸

Research Site, Zaragoza, Spain

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

Phase 4
Completed
Conditions
Healthy
First Posted Date
2005-10-03
Last Posted Date
2013-01-04
Lead Sponsor
AstraZeneca
Target Recruit Count
100
Registration Number
NCT00230516
Locations
🇺🇸

Research Site, Oklahoma City, Oklahoma, United States

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Phase 2
Completed
Conditions
Indigestion
Interventions
Other: Placebo
Drug: Esomeprazole
First Posted Date
2005-09-22
Last Posted Date
2019-11-27
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
73
Registration Number
NCT00222131
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

Phase 4
Completed
Conditions
Healthy
First Posted Date
2005-09-21
Last Posted Date
2011-01-21
Lead Sponsor
AstraZeneca
Target Recruit Count
40
Registration Number
NCT00206050
Locations
🇺🇸

Research Site, Oklahoma City, Oklahoma, United States

Nexium Study To Suppress Nausea During Chemotherapy

Phase 3
Terminated
Conditions
Nausea
Interventions
Other: Placebo
Drug: esomeprazole
First Posted Date
2005-09-21
Last Posted Date
2018-12-06
Lead Sponsor
Baylor Breast Care Center
Target Recruit Count
43
Registration Number
NCT00206440
Locations
🇺🇸

Baylor Breast Center, Houston, Texas, United States

On Demand Treatment of Reflux Disease

Phase 4
Completed
Conditions
Gastroesophageal Reflux
Interventions
Drug: Aflurax
Drug: esomeprazole
First Posted Date
2005-09-16
Last Posted Date
2011-08-09
Lead Sponsor
Norwegian University of Science and Technology
Target Recruit Count
82
Registration Number
NCT00184522
Locations
🇳🇴

Gjøvik Specialist Centre, Gjøvik, Norway

🇳🇴

Sykehuset Innlandet HF, Hamar, Hamar, Norway

🇳🇴

Sykehuset Innlandet HF, Gjøvik, Gjøvik, Norway

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy